Novel Cell-Based Therapies
Treating Solid Tumors
Solid tumors create conditions that inhibit the functions of immune cells and escape destruction. In order to restore the ability of NK cells to kill the tumor cells, it is necessary to create modified NK cells that will overcome the ways in which solid tumors can inhibit normal NK cells.
Our observations show that, in cell culture, normal NK-cells kill melanoma cells due to the lack of immunosuppressant factors. However, when we add those factors to the medium, normal NK-cells are completely inactive against the melanoma cells.
We are pioneering next-generation cancer treatments through precision science, innovative research, and a commitment to transforming patient outcomes worldwide.
The NK cells developed by us continue to grow and kill metastatic tumor cells in the presence of high levels of immunosuppressive factors.
We expect to complete R&D for the first indication within six months and begin a campaign for a series A raise to take us into preclinical studies and a Phase 1/2A clinical trial
